Royalty Pharma Announces Agreement Regarding the Purchase of the Rights to a Pre-Existing Royalty Interest in HUMIRA® from AstraZeneca and CAT

New York, NY, October 26, 2006 – Royalty Pharma announced today that it has completed the purchase of the rights to a pre-existing royalty interest in HUMIRA® currently held by AstraZeneca plc’s subsidiary, Cambridge Antibody Technology Limited (CAT).

Source: Original Article